Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Research Report 2024

Publication ID:

PB502244252

Publication Date:

February 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hemophilia A and B Recombinant Factor Replacement Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia A and B Recombinant Factor Replacement Therapy.
Report Scope
The Hemophilia A and B Recombinant Factor Replacement Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia A and B Recombinant Factor Replacement Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemophilia A and B Recombinant Factor Replacement Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure
Segment by Type
Haemophilia A
Haemophilia B
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemophilia A and B Recombinant Factor Replacement Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Haemophilia A
1.2.3 Haemophilia B
1.3 麻豆原创 by Application
1.3.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Perspective (2019-2030)
2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Growth Trends by Region
2.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Dynamics
2.3.1 Hemophilia A and B Recombinant Factor Replacement Therapy Industry Trends
2.3.2 Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Drivers
2.3.3 Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Challenges
2.3.4 Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Revenue
3.1.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Revenue (2019-2024)
3.1.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue
3.4 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2023
3.5 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players Head office and Area Served
3.6 Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
3.7 Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemophilia A and B Recombinant Factor Replacement Therapy Breakdown Data by Type
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 Hemophilia A and B Recombinant Factor Replacement Therapy Breakdown Data by Application
5.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size (2019-2030)
6.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2019-2024)
6.4 North America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size (2019-2030)
7.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size (2019-2030)
9.2 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.1.4 Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.2.4 Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.2.5 Novo Nordisk Recent Development
11.3 Baxalta
11.3.1 Baxalta Company Detail
11.3.2 Baxalta Business Overview
11.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.3.4 Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.3.5 Baxalta Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.4.4 Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Biogen
11.5.1 Biogen Company Detail
11.5.2 Biogen Business Overview
11.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.5.4 Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.5.5 Biogen Recent Development
11.6 CSL Behring
11.6.1 CSL Behring Company Detail
11.6.2 CSL Behring Business Overview
11.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.6.4 CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.6.5 CSL Behring Recent Development
11.7 Emergent Biosolutions
11.7.1 Emergent Biosolutions Company Detail
11.7.2 Emergent Biosolutions Business Overview
11.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.7.4 Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.7.5 Emergent Biosolutions Recent Development
11.8 Spark therapeutics
11.8.1 Spark therapeutics Company Detail
11.8.2 Spark therapeutics Business Overview
11.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.8.4 Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.8.5 Spark therapeutics Recent Development
11.9 Uniqure
11.9.1 Uniqure Company Detail
11.9.2 Uniqure Business Overview
11.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.9.4 Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2019-2024)
11.9.5 Uniqure Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.